🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05645055
Recruiting Observational

Biologics for Stricturing Crohn's Diseases

NCT05645055 · tracked via the Priya Life Science China tracker
Sponsor
Jinling Hospital, China
Phase
Observational
Started
2021-01-01
Last updated
2023-05-11

Condition(s) studied

The Efficacy of Biologics for Stricturing Crohn's Diseases

Investigational drug(s) / intervention(s)

treat these patients with biologics

treat these patients with biologics: treat these patients with biologics

Study summary

Recent researches have reported that biologics might be also effective for stricturing CD. However, the data were largely retrospective. Prospective studied are needed for evaluate the efficacy of biologics for stricturing Crohn's diseases.

Eligibility

Sex
ALL
Min age
16 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * patients with stricturing Crohn's diseases * no surgical indication * patients with asymptomatic penetrating diseases * written consent acquired Exclusion Criteria: * patients with surgical indication * patients with symptomatic penetrating diseases * contraindication of biologics * anticipating other trial

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of General Surgery, Jinling hosptal,Medical School of Nanjing University Nanjing Jiangsu Recruiting

More Jinling Hospital, China trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05645055 on ClinicalTrials.gov ↗ ← All trials in China